|
1
|
Response and remission criteria in major depression--a validation of current practice.
|
J Psychiatr Res
|
2010
|
1.52
|
|
2
|
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia.
|
J Clin Psychopharmacol
|
2003
|
1.43
|
|
3
|
Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.
|
J Clin Psychiatry
|
2010
|
1.07
|
|
4
|
Predictors of relapse in the year after hospital discharge among patients with schizophrenia.
|
Psychiatr Serv
|
2012
|
1.00
|
|
5
|
MAO-inhibitors in Parkinson's Disease.
|
Exp Neurobiol
|
2011
|
0.97
|
|
6
|
Antidepressants and driving ability: results from a clinical study.
|
J Clin Psychiatry
|
2006
|
0.94
|
|
7
|
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.
|
Eur Arch Psychiatry Clin Neurosci
|
2014
|
0.93
|
|
8
|
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
|
J Psychiatr Res
|
2005
|
0.93
|
|
9
|
Outcomes of 1014 naturalistically treated inpatients with major depressive episode.
|
Eur Neuropsychopharmacol
|
2010
|
0.93
|
|
10
|
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
|
Schizophr Res
|
2009
|
0.92
|
|
11
|
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.
|
Eur Arch Psychiatry Clin Neurosci
|
2014
|
0.92
|
|
12
|
Clinical predictors of response and remission in inpatients with depressive syndromes.
|
J Affect Disord
|
2011
|
0.89
|
|
13
|
The impact of antipsychotics on psychomotor performance with regards to car driving skills.
|
J Clin Psychopharmacol
|
2004
|
0.88
|
|
14
|
The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients.
|
J Clin Psychiatry
|
2008
|
0.88
|
|
15
|
Attitude towards adherence in patients with schizophrenia at discharge.
|
J Psychiatr Res
|
2009
|
0.87
|
|
16
|
[Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine]
|
Psychiatr Prax
|
2003
|
0.86
|
|
17
|
The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode.
|
Int J Neuropsychopharmacol
|
2008
|
0.85
|
|
18
|
Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials.
|
J Clin Psychiatry
|
2010
|
0.85
|
|
19
|
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.
|
J Clin Psychopharmacol
|
2010
|
0.85
|
|
20
|
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
|
Dialogues Clin Neurosci
|
2005
|
0.84
|
|
21
|
Driving ability in schizophrenic patients: effects of neuroleptics.
|
Int J Psychiatry Clin Pract
|
2005
|
0.84
|
|
22
|
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.
|
Psychopathology
|
2012
|
0.83
|
|
23
|
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.
|
Psychiatry Res
|
2008
|
0.83
|
|
24
|
Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?
|
Neurotox Res
|
2010
|
0.83
|
|
25
|
Response trajectories in "real-world" naturalistically treated schizophrenia patients.
|
Schizophr Res
|
2012
|
0.82
|
|
26
|
Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics.
|
Eur Arch Psychiatry Clin Neurosci
|
2009
|
0.81
|
|
27
|
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
|
J Psychiatr Res
|
2011
|
0.81
|
|
28
|
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
|
World J Biol Psychiatry
|
2010
|
0.81
|
|
29
|
Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram.
|
Ther Drug Monit
|
2013
|
0.81
|
|
30
|
Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders.
|
Eur Arch Psychiatry Clin Neurosci
|
2007
|
0.80
|
|
31
|
Prediction of symptom remission in schizophrenia during inpatient treatment.
|
World J Biol Psychiatry
|
2009
|
0.80
|
|
32
|
One-year functional outcomes of naturalistically treated patients with schizophrenia.
|
Psychiatry Res
|
2012
|
0.80
|
|
33
|
Association between citalopram serum levels and clinical improvement of patients with major depression.
|
J Clin Psychopharmacol
|
2011
|
0.78
|
|
34
|
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.
|
Psychiatr Q
|
2012
|
0.77
|
|
35
|
Cannabinoids improve driving ability in a Tourette's patient.
|
Psychiatry Res
|
2011
|
0.77
|
|
36
|
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
|
Psychiatr Prax
|
2003
|
0.76
|
|
37
|
[Antipsychotics and memory functions in schizophrenic patients].
|
Psychiatr Prax
|
2004
|
0.76
|
|
38
|
[Driving capacity and antidepressive drugs].
|
Psychiatr Prax
|
2003
|
0.75
|
|
39
|
The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review : 70th Birthday Prof. Riederer.
|
J Neural Transm (Vienna)
|
2012
|
0.75
|
|
40
|
[When the typical family doctor patient needs a psychotropic drug. The most important guidelines for therapy].
|
MMW Fortschr Med
|
2006
|
0.75
|
|
41
|
[What are the differences between a year later remitted and non-remitted depressive patients? Results of a retrospective long-term study at the Bezirksklinikum Gabersee].
|
Psychiatr Prax
|
2004
|
0.75
|
|
42
|
Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigine.
|
J Clin Pharmacol
|
2013
|
0.75
|
|
43
|
[Depression and response: impact of personality and cognition].
|
Psychiatr Prax
|
2009
|
0.75
|
|
44
|
[Driving ability in mental illness].
|
MMW Fortschr Med
|
2015
|
0.75
|
|
45
|
[Erythema multiforme caused by carbamazepine].
|
Psychiatr Prax
|
2004
|
0.75
|
|
46
|
Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine.
|
Ther Drug Monit
|
2013
|
0.75
|
|
47
|
[Aggression of psychiatric patients--first results of a standardized documentation at the Gabersee district hospital].
|
Psychiatr Prax
|
2003
|
0.75
|
|
48
|
[QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].
|
Psychiatr Prax
|
2004
|
0.75
|
|
49
|
[Antidepressants and Driving Ability]
|
Psychiatr Prax
|
2003
|
0.75
|
|
50
|
[Neuroleptics and cognition].
|
Psychiatr Prax
|
2003
|
0.75
|